Can-Fite Biopharma (NYSE-MKT: CANF)

Tiny float, bottomed over sold chart, at/near 52 week lows and on the verge of biotech breakthrough. This one could move fast this week with such a low share structure and perfect chart setup.

Can-Fite Biopharma (NYSE-MKT: CANF)

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company’s CF101 is in Phase II/III trials for the treatment of psoriasis and just completed successful Phase II trials for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 Phase II trial will start enrolling patients shortly. CF102 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and is approved for Compassionate Use by Israel’s Ministry of Health. The Company’s drug candidates have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. The Company’s intellectual property portfolio consists of 150 patents issued and pending.

(NYSE-MKT: CANF) Highlights

Nothing but the facts: http:// http://smallcapir.com/wp-content/uploads/2014/11/2014-11-04-CANF-FactSheet_FINAL1.pdf

Power Point Presentation: http://smallcapir.com/wp-content/uploads/2014/11/11-7-2014-Can-Fite-Presentation-BR_FINAL0001-1.pdf

Older Analysis by Roth Capital with $15 price target, prior to the up list to the NYSE: http://smallcapir.com/wp-content/uploads/2014/11/ROTH-Capital-Analysis-1.pdf

This should get everyone in our group familiar with Can-Fite Biopharma for now.
Please share this article

Monthly Gold & Silver Stock Update: SA, XRA, GORO, TGD, IO, TLR, SVLC, SCZ, FSM

The U.S. Fed’s announcement in October that it was ending quantitative easing capped a tough month for precious metal producers. The news led triggered another wave of selling in gold dropping under $1,200 and silver falling even more aggressively to under $16. The fall only compounds challenges for producers whose third quarter results already show stress from the metal prices.

A technical perspective shows the breach of $1,180 area, a key support level, creating more problems for gold. Unless the price can recover back and hold above, the next downside target should take the price to the $1,088 Fibonacci support area.

The renewed wave of fear has hit gold-silver stocks very hard with 2008 lows now being re-tested. If the gold-silver prices can find a bottom soon, and it could have very well put it has in this past week, then I expect that these stock prices will reverse dramatically. But until the fear of much lower gold and silver prices subsides, negative pressures will dominate and volatility will be at historic levels.

SEABRIDGE GOLD continues to expand its KSM deposit, with new drill results expanding the potential of the Iron Cap Lower Zone including an impressive 593 metre-intercept grading 1.14 g/t gold and 0.37% copper. The company has traced the zone for 750 metres and it is still open to the north and at depth. With so many results coming in Seabridge expects to have a first resource estimate out on the new zone in the first quarter of 2015.  (more)

Please share this article

The Future of Corn & Ethanol Prices

Corn is a major feedstock for domestic ethanol production, when corn prices move, expect ethanol to follow closely behind.
Roughly a third of domestic corn is used to produce ethanol, and with harvests starting earlier and ending later, that number is only projected to rise.
However, the relationship between corn and ethanol isn't that simple. In the event of a corn surplus, ramped-up ethanol production alone can't entirely stem the overflow from corn inventories, but it will assist in limiting the price fallout from the build-up. (more)

Please share this article

S&P 500 Hits Goldman Sachs Year-End 2,050 Target

zerohedge.com / by Tyler Durden on 11/18/2014 11:38
It’s been quite a year for David Kostin and his flip-flopping Goldman equity strategy team. From a modest 1,900 year-end target in January (reached in May) to warning stocks are 30-45% overvalued in January to projecting the S&P 500 will reach 2,050 by year-end in July…Mission Accomplished today, 6 weeks early. Now what?
Mission Accomplished…

READ MORE
Please share this article

This Tiny Aussie Oil Stock Could Be a Big Winner in China’s Latest Trade Deal: Linc Energy Ltd. (OTC:LNCGY)

The U.S.-Chinese accord on climate control may have grabbed the most headlines yesterday, but the trade pact signed between China and Australia is likely to have a much bigger impact.
In the shadows of the G20 meeting in Brisbane, Canberra inked a free trade agreement with Beijing that will see tariffs on all resources and energy products removed within two years.
By agreeing to the deal, Australia will now reap the benefits of zero tariffs on major exports like iron ore, gold, crude oil, and liquefied natural gas (LNG). (more)

Please share this article

3 Cheap Dividend Stocks Under $10: LOAN, NKA , GAIN

There are pros and cons with cheap dividend stocks — and by “cheap,” I mean in absolute dollar terms. These are stocks generally below $10 per share.
The upside of cheap dividend stocks is that they are cheap on an absolute dollar basis, and have been sold off to a point where analysts and other investors lose interest. (more)

Please share this article